Subsidiary of Solvay Pharmaceuticals. For more information, please visitSolvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company wants to carefully selected information please visit therapeutic areas of neuroscience, cardio – metabolic, influenza vaccines, gastroenterology, specialized markets and men ‘s and women’s health. Its 2005 sales of EUR 2.3 billion and employs approximately 10,000 people worldwide. For more information, please visit – SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels. The company employs approximately 30,000 people in 50 countries. In 2005, its consolidated sales amounted to EUR 8, generated by its three activity sectors: Chemicals, Plastics and Pharmaceuticals.
Solvay Pharmaceuticals, Wyeth Pharmaceuticals, a division of Wyeth and Lundbeck A / S presented clinical study results for bifeprunox at a major medical conference this week. Bifeprunox an investigational treatment for schizophrenia than daily dosing is examined. The results of this efficacy and safety studies showed that in a six month study bifeprunox stability obtained in patients with stable schizophrenia versus placebo. In six-week trials, bifeprunox improved symptoms in patients with acute exacerbation of schizophrenia but showed a smaller mean effect than did active references versus placebo.Stern team have many new four – year, $ 1,000 grant from the the Department of Defense Neurofibromatose Research Program at in order to develop the fruitfly model of to neurofibromatosis and several major proteins as it is already been play an important role into identify AF obtained try.